Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Setsuko K Chambers

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Scientific Reports|December 2, 2024
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer riskXia Wang, Ho-Hyung Woo, Michelle Wei, et al.
Journal of Cancer|September 16, 2010
Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature reviewRebecca L Klein, Amanda R Brown, Christian M Gomez-Castro, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2024
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer RiskXia Wang, Ho-Hyung Woo, Michele Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2014
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904Robert L Coleman, James Moon, Anil K Sood, et al.
Experimental Biology and Medicine (Maywood, N.J.)|March 7, 2014
Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imagingJustin J Jeffery, Katie Lux, John S Vogel, et al.
Oncotarget|January 30, 2016
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathwayYiying Wang, Yue Wang, Zhenbo Zhang, et al.
Investigational New Drugs|May 15, 2012
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancerAmanda F Baker, Denise J Roe, Cynthia Laughren, et al.
International Journal of Cancer|May 18, 2010
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or youngerSharon X Liang, Micheal Pearl, Shu Liang, et al.
The Journal of Supportive Oncology|January 27, 2011
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancerLisa M Hess, Setsuko K Chambers, Kenneth Hatch, et al.
Molecular Imaging and Biology|November 30, 2016
Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRIKyle M Jones, Edward A Randtke, Eriko S Yoshimaru, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Scientific Reports|December 2, 2024
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer riskXia Wang, Ho-Hyung Woo, Michelle Wei, et al.
Journal of Cancer|September 16, 2010
Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature reviewRebecca L Klein, Amanda R Brown, Christian M Gomez-Castro, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2024
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer RiskXia Wang, Ho-Hyung Woo, Michele Wei, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2014
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904Robert L Coleman, James Moon, Anil K Sood, et al.
Experimental Biology and Medicine (Maywood, N.J.)|March 7, 2014
Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imagingJustin J Jeffery, Katie Lux, John S Vogel, et al.
Oncotarget|January 30, 2016
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathwayYiying Wang, Yue Wang, Zhenbo Zhang, et al.
Investigational New Drugs|May 15, 2012
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancerAmanda F Baker, Denise J Roe, Cynthia Laughren, et al.
International Journal of Cancer|May 18, 2010
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or youngerSharon X Liang, Micheal Pearl, Shu Liang, et al.
The Journal of Supportive Oncology|January 27, 2011
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancerLisa M Hess, Setsuko K Chambers, Kenneth Hatch, et al.
Molecular Imaging and Biology|November 30, 2016
Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRIKyle M Jones, Edward A Randtke, Eriko S Yoshimaru, et al.
Pageof 7